Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

Delayed Quote. Delayed  - 09/28 10:00:00 pm
14.14 USD   +1.36%
01:36p ARIAD PHARMACEU : Announces Regulatory Approval for Iclusig® (ponati..
09/15 ARIAD PHARMACEU : Announces Ponatinib Data Presentations at European..
08/30 ARIAD PHARMACEU : Completes Rolling Submission of New Drug Applicati..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2016 09/23/2016 09/26/2016 09/27/2016 09/28/2016 Date
13.63(c) 13.52(c) 13.96(c) 13.95(c) 14.14 Last
9 314 659 6 726 009 6 325 652 6 869 062 5 950 328 Volume
+1.64% -0.81% +3.25% -0.07% +1.36% Change
More quotes
Financials ($)
Sales 2016 189 M
EBIT 2016 -120 M
Net income 2016 -52,6 M
Debt 2016 150 M
Yield 2016 -
Sales 2017 227 M
EBIT 2017 -78,2 M
Net income 2017 -111 M
Debt 2017 189 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 15,0x
EV / Sales2017 12,7x
Capitalization 2 688 M
More Financials
Company
ARIAD Pharmaceuticals, Inc. operates as an oncology company which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer.Its products include Iclusig and Caregivers.The company was founded by Harvey J. Berger in April 1991 and is... 
More about the company
Surperformance© ratings of Ariad Pharmaceuticals, Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ARIAD PHARMACEUTICALS, INC
01:36p ARIAD PHARMACEUTICALS : Announces Regulatory Approval for Iclusig® (ponatinib) i..
09/15 ARIAD PHARMACEUTICALS : Announces Ponatinib Data Presentations at European Schoo..
09/09 ARIAD PHARMACEUTICALS : to Present at the Morgan Stanley Global Healthcare Confe..
09/09 ARIAD PHARMACEUTICALS : Completes Rolling Submission of New Drug Application for..
08/30 ARIAD PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (for..
08/30 ARIAD PHARMACEUTICALS : Completes Rolling Submission of New Drug Application for..
08/29 ARIAD PHARMACEUTICALS : to Present at the Morgan Stanley Global Healthcare Confe..
08/11 PDL BIOPHARMA : Completes Second Tranche Payment Under Royalty Transaction with ..
08/08 ARIAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
08/01 ARIAD PHARMACEUTICALS : PDL BioPharma Completes Second Tranche Payment Under Roy..
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08:00a Iclusig OK'd in Japan; ARIAD shares up 2% premarket
09/24 BIOTECH : What's Next For M&A?
09/15 BIOTECHNOLOGY : No Easy Way Out But Almost There!
09/13 Staying The Course! Stocks Remain Attractive
08/31 Ariad Is Rolling Right On Track In Q3 With Its Lung Cancer Drug
Advertisement
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 11,6 $
Spread / Average Target -17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paris Panayiotopoulos President, Chief Executive Officer & Director
Alexander John Denner Chairman
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Nicholas Ventresca Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..123.20%2 690
AMGEN, INC.5.73%129 863
GILEAD SCIENCES, INC.-21.68%106 391
CELGENE CORPORATION-10.32%82 402
REGENERON PHARMACEUTIC..-22.37%42 552
VERTEX PHARMACEUTICALS..-29.17%21 876
More Results